See how Novartis is responding to Coronavirus (COVID-19)
This site is intended for UK healthcare professionals only. If you are a member of the public, please click here
Pyrexia was the most common adverse event observed in Phase III clinical trials of Tafinlar (dabrafenib) + Mekinist (trametinib).
This brochure is designed to provide guidance on how to monitor your patients for the onset of pyrexia and advises on how best to manage pyrexia to allow continued treatment with Tafinlar + Mekinist.
Images provided for preview. Please contact your Novartis Representative to receive a copy of this brochure.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]
